Form 4 Filing for Beta Bionics, Inc. - Insider Transaction

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., reported a sale of 370 shares of Common Stock on October 1, 2026, at a price of $18.96 per share. This transaction was executed under a Rule 10b5-1 Plan adopted on June 10, 2026. Following the sale, Mr. Hopman holds 56,109 shares of Common Stock. The weighted average sale price was $18.96, with a range between $18.96 and $19.9599. Full details on shares sold at each specific price will be provided upon request by the SEC, the Issuer, or any security holder.